WilmerHale Advises Thermo Fisher on $1.2B USD and €1.25B EUR Notes Offerings

Download IconDownload Print IconPrint

WilmerHale Advises Thermo Fisher on $1.2B USD and €1.25B EUR Notes Offerings

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented Thermo Fisher Scientific Inc. in connection with its public offering of €500.0 million aggregate principal amount of 3.200% Senior Notes due 2026 and €750.0 million aggregate principal amount of 3.650% Senior Notes due 2034 and its public offering of $600.0 million aggregate principal amount of 4.800% Senior Notes due 2027 and $600.0 million aggregate principal amount of 4.950% Senior Notes due 2032. Both offerings were priced on November 14, 2022 and closed on November 21, 2022. Citigroup Global Markets Limited, Deutsche Bank AG, London Branch and Merrill Lynch International acted as representatives of the underwriters for the Eurobond offering and BofA Securities, Inc., Citigroup Global Markets Inc. and Deutsche Bank Securities Inc. acted as representatives of the underwriters for the US dollar-denominated offering.

The WilmerHale legal team advising Thermo Fisher Scientific Inc on both offerings consisted of Erika Robinson, Justin Ochs, Molly Fox, Timothy Silva, Julie Hogan-Rodgers, Andrew Langworthy, Ryan S. Brewer, Ryan Lombardo, Ben Lobley and Mazen Osman.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel